advertisement
Abstract #6875 Published in IGR 4-1
Twelve-month evaluation of brimonidine-Purite versus brimonidine in patients with glaucoma or ocular hypertension
Katz LJJournal of Glaucoma 2002; 11: 119-126
PURPOSE: To compare the efficacy and safety of brimonidine-Purite (Alphagan; Allergan, Irvine, CA) 0.15 and 0.2% three times daily with brimonidine (Alphagan) 0.2% three times daily in patients with glaucoma or ocular hypertension. PATIENTS AND METHODS: In this 12-month, randomized, multicenter, double-masked, parallel-group study, patients were randomly assigned to receive brimonidine-Purite 0.15% (n = 381), brimonidine-Purite 0.2% (n = 383), or brimonidine 0.2% (n = 383) three times daily. Visits were conducted before the study, at baseline, at weeks 2 and 6, and at months 3, 6, 9, and 12. Diurnal intraocular pressure (IOP) was measured at 8 a.m., 10 a.m., 3 p.m., and 5 p.m. at baseline, week 6, and at months 3, 6, and 12. IOP was also measured at 8 and 10 a.m. at week 2 and month 9. Safety was evaluated by adverse events and other ocular and systemic measures. RESULTS: At baseline, mean IOP was similar in the three treatment groups. During follow-up, there were no statistically significant among-group differences in mean IOP or mean changes from baseline intraocular pressure (at peak or trough). The difference in mean intraocular pressure between the brimonidine-Purite-0.15% and brimonidine-0.2% treatment group was less than 1 mmHg at all time points. The relative percent difference in allergic conjunctivitis was 41% lower in the brimonidine-Purite 0.15% group compared with the brimonidine 0.2% group. The comfort and satisfaction rating significantly favored brimonidine-Purite 0.15%. CONCLUSIONS: Over 12 months, brimonidine-Purite 0.15% and 0.2% provided IOP lowering comparable to brimonidine 0.2% in patients with glaucoma or ocular hypertension. Brimonidine-Purite 0.15% showed the most favorable safety and tolerability profile with a reduced incidence of allergic conjunctivitis and better satisfaction and comfort rating.
Dr. L.J. Katz, Brimonidine-Purite Study Groups 1 and 2, Wills Eye Hospital, Philadelphia, PA, USA
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
